Veristrat is a new test that was presented in April 2012. at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The Veristrat test was validated through a retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy of Avastin and plus erlotinib. This means that after the study was finished, the researchers when back and checked tissue samples with Veristrat and then looked to see what happened to patients whose cases they analyzed. Veristrat test was able to identify patients likely to have better and worse survival outcomes in these trials.
A similar analysis of the Phase III trial, EGF30008, was presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. Results showed that the Veristrat test was able to identify a group of patients whose breast cancer came back sooner when treated with Femara alone.
Veristrat test may eventually become accepted to be useful for clinical decision-making, representing about treatment with erlotinib and erlotinib combinations. Prospective trials are ongoing, including a Phase III trial in advanced squamous cell lung cancer, sponsored by the European Thoracic Oncology group. Once these are reported and analyzed, Veristrat may join the current treatment armamentarium but it is still premature to make treatment decisions based on a retrospective analysis. Generally, showing that a test is predictive is not enough. Researchers need to show that selecting treatments based on a test has a beneficial result.
Read the Professional version here.